An Open-Label One-Way Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Sunitinib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 04 Dec 2009 Biomarkers information updated
- 30 May 2009 New trial record